Recce Pharmaceuticals Gestion

Gestion contrôle des critères 3/4

Le PDG Recce Pharmaceuticals est James Graham, nommé en Aug2020, a un mandat de 4.25 ans. La rémunération annuelle totale est A$ 834.51K, composée du salaire de 62.8% et des bonus 37.2%, y compris les actions et options de la société. détient directement 2.92% des actions de la société, d'une valeur de € 1.93M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.2 ans et 6 ans.

Informations clés

James Graham

Directeur général

AU$834.5k

Rémunération totale

Pourcentage du salaire du PDG	62.8%
Durée du mandat du directeur général	4.3yrs
Propriété du PDG	2.9%
Durée moyenne d'occupation des postes de direction	4.2yrs
Durée moyenne du mandat des membres du conseil d'administration	6yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de James Graham a-t-elle évolué par rapport aux bénéfices de Recce Pharmaceuticals?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	AU$835k	AU$524k	-AU$18m
Mar 31 2024	n/a	n/a	-AU$14m
Dec 31 2023	n/a	n/a	-AU$11m
Sep 30 2023	n/a	n/a	-AU$12m
Jun 30 2023	AU$775k	AU$551k	-AU$13m
Mar 31 2023	n/a	n/a	-AU$14m
Dec 31 2022	n/a	n/a	-AU$15m
Sep 30 2022	n/a	n/a	-AU$13m
Jun 30 2022	AU$548k	AU$328k	-AU$11m
Mar 31 2022	n/a	n/a	-AU$10m
Dec 31 2021	n/a	n/a	-AU$8m
Sep 30 2021	n/a	n/a	-AU$11m
Jun 30 2021	AU$2m	AU$294k	-AU$14m
Mar 31 2021	n/a	n/a	-AU$13m
Dec 31 2020	n/a	n/a	-AU$13m
Sep 30 2020	n/a	n/a	-AU$9m
Jun 30 2020	AU$216k	AU$187k	-AU$4m
Mar 31 2020	n/a	n/a	-AU$4m
Dec 31 2019	n/a	n/a	-AU$3m
Sep 30 2019	n/a	n/a	-AU$3m
Jun 30 2019	AU$177k	AU$155k	-AU$3m
Mar 31 2019	n/a	n/a	-AU$2m
Dec 31 2018	n/a	n/a	-AU$2m
Sep 30 2018	n/a	n/a	-AU$2m
Jun 30 2018	AU$160k	AU$142k	-AU$2m

Rémunération vs marché: La rémunération totale de James ($USD 548.44K ) est dans la moyenne des entreprises de taille similaire sur le marché German ($USD 483.75K ).

Rémunération et revenus: La rémunération de James a augmenté alors que l'entreprise n'est pas rentable.

PDG

James Graham

4.3yrs

Titularisation

AU$834,509

Compensation

Mr. James Hamilton-Bray Graham, B.Com. (Entrepreneurship), GAICD, serves as Chief Executive Officer at Recce Pharmaceuticals Ltd since August 28, 2020 and also serves as Managing Director since 2020. He ha...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
John K. Prendergast	Executive Chairman of the Board	6.6yrs	AU$380.55k	0.13% € 87.3k
James Graham	CEO, MD & Executive Director	4.3yrs	AU$834.51k	2.92% € 1.9m
Michele Dilizia	Chief Scientific Director & Executive Director	4.2yrs	AU$530.84k	1.33% € 878.1k
Justin Ward	Principal Quality Chemist & Executive Director	no data	AU$318.53k	0.13% € 85.8k
Arthur Kollaras	Principal Engineer & Head of Manufacturing	no data	AU$564.01k	0.040% € 26.2k
Alan Dunton	Chief Medical Advisor & Independent Non Executive Director	no data	AU$75.00k	0.055% € 36.1k
Justin Reynolds	Chief Financial Officer	7yrs	pas de données	pas de données
Daniel Astudillo	Head of Marketing	4.8yrs	pas de données	pas de données
Maggie Niewidok	Company Secretary	2.2yrs	pas de données	pas de données

4.2yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de R9Q est considérée comme expérimentée (ancienneté moyenne 4.2 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
John K. Prendergast	Executive Chairman of the Board	6.6yrs	AU$380.55k	0.13% € 87.3k
James Graham	CEO, MD & Executive Director	9.4yrs	AU$834.51k	2.92% € 1.9m
Michele Dilizia	Chief Scientific Director & Executive Director	9.4yrs	AU$530.84k	1.33% € 878.1k
Justin Ward	Principal Quality Chemist & Executive Director	5.3yrs	AU$318.53k	0.13% € 85.8k
Alan Dunton	Chief Medical Advisor & Independent Non Executive Director	4.3yrs	AU$75.00k	0.055% € 36.1k
Alistair McKeough	Non-Executive Director	2.2yrs	AU$81.25k	0.011% € 7.4k

6.0yrs

Durée moyenne de l'emploi

Conseil d'administration expérimenté: Les membres du conseil d'administration de R9Q sont considérés comme expérimentés (ancienneté moyenne 6 ans).

Recce Pharmaceuticals Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 06, 2024

CEO, MD & Executive Director recently bought €190k worth of stock

Less than half of directors are independent

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 14, 2022

Recce Pharmaceuticals Appoints Alistair McKeough to Its Board of Directors and Maggie Niewidok as Company Secretary

Recce Announces Management Changes

Recent updates

Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections

Recce Pharmaceuticals Announces Recruitment Passes Halfway in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 06, 2024

New major risk - Revenue and earnings growth

Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter Baumannii

Recce Pharmaceuticals Ltd has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Recce Pharmaceuticals Reports Positive Data from Phase I/Ii Urinary Tract Infection (Uti) / Urosepsis Rapid Infusion Trial of Recce® 327

Recce Pharmaceuticals Ltd. Receives Ethics Approval to Broaden RECCE 327 Gel Trials Across All Topical Bacterial Skin Infections

Recce Pharmaceuticals Announces Addition of RECCE® 327 to the World Health Organization’S List of Antibacterial Products in Clinical Development

Recce Pharmaceuticals Ltd Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial

Recce Pharmaceuticals Reports Positive Preclinical Data of Recce® 327 in Lung Infection Pilot Study

Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration

New major risk - Revenue and earnings growth

Recce Pharmaceuticals Ltd. Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice

Recce Pharmaceuticals Ltd Receives New Patent in Israel for Recce Anti-Infectives

New major risk - Revenue and earnings growth

Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of Recce® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd Doses Next Cohort in Phase I/II Trial of RECCE 327 for Urinary Tract Infections and Urosepsis

New major risk - Share price stability

Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE 327 for the Treatment of Diabetic Foot Infections

Recce Pharmaceuticals Receives Ausindustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program

Recce Pharmaceuticals Ltd Reports Positive Preclinical Data of RECCE 327 Against Gonorrhoeae

Recce Pharmaceuticals Limited Announces Canadian Patent Granted for Recce® Anti-Infectives

Recce Pharmaceuticals Ltd Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd Announces Safety Committee Approves Faster Infusion Rate in Phase I/Ii Trial of Recce® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million.

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million.

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.715261 million.

Recce Pharmaceuticals Completes Dosing in Phase I/II Clinical Trial of Recce® 327 for Urinary Tract Infections

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 8 million.

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 8 million.

Recce Pharmaceuticals Ltd Provides Additional Positive Update on Patients Treated Under "Special Access Scheme"

New minor risk - Financial data availability

Recce Pharmaceuticals Ltd Announces Safety Committee Approves Next Dose of Recce®? 327 At 3,000Mg in Phase I/Iiuti/Urosepsis Rapid Infusion Clinical Trial

Recce Pharmaceuticals Ltd Doses Patients in Phase I/II Clinical Trial of Recce 327 for Diabetic Foot Infections

Recce Pharmaceuticals Ltd. Completes Stage 1 Data Analysis of Phase I/II Clinical Trial for the Treatment of Burn Wound Infections

Recce Pharmaceuticals Ltd Provides Positive Update on Patients Treated with RECCE®? 327 Under "Special Access Scheme"

New major risk - Share price stability

Recce Pharmaceuticals Completes First Cohort Dosing of Phase l/ll UTI Rapid Infusion Clinical Trial at Scientia Clinical Research

Recce Pharmaceuticals Achieves Positive Phase I Clinical Trial Data of RECCE(R) 327 as an Intravenous Infusion Formulation

Recce Pharmaceuticals Limited Announces First Cohort Dosed in Recce®? 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial

CEO, MD & Executive Director recently bought €190k worth of stock

Recce Pharmaceuticals to Be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Recce Pharmaceuticals Limited Announces Australian Patent Office Issued Notification of Intent to Grant Recce's Patent Family 3

Recce Pharmaceuticals Ltd Receives Ethics Approval to Start Phase 1/2 Study Evaluating RECCE(R) 327 in Patients with Diabetic Foot Infections

Recce Pharmaceuticals Ltd Receives Ethics Approval to Start Phase I/II Diabetic Foot Ulcer Study

Less than half of directors are independent

Recce Pharmaceuticals Ltd Provides RECCE 327 SARS-CoV-2 Study Update

Recce Pharmaceuticals Ltd Provides RECCE 327 SARS-CoV-2 Study Update

Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 14, 2022

Recce Pharmaceuticals Appoints Alistair McKeough to Its Board of Directors and Maggie Niewidok as Company Secretary

Recce Announces Management Changes

Recce Pharmaceuticals Ltd Reports Positive Safety Data from Seventh Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327

Recce Pharmaceuticals Ltd announces Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE 327 and Initiates Sixth Cohort At 4,000Mg

Less than half of directors are independent

Recce Pharmaceuticals Ltd Announces Anti-Viral Patent Granted in Hong Kong

Recce Pharmaceuticals Ltd Announces Safety Committee Clears Next Dose in Phase I Study of Recce® 327

Recce Pharmaceuticals Ltd Announces Positive Safety Data from Second Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327

Recce Pharmaceuticals Ltd Announces Patients to be Dosed in a Phase I Intravenous Clinical Trial of RECCE® 327

Anti-Viral Patent Grants in USA for Recce Pharmaceuticals Ltd's RECCE Anti-Infectives

Chinese Patent Office Grants Anti-Viral Patent to Recce Pharmaceuticals Ltd

Board Member recently sold €113k worth of stock

Recce Pharmaceuticals Ltd. Provides Recce Clinical Pipeline Update

Recce Pharmaceuticals Ltd Announces Positive Results of Lead Compound RECCE® 327

Recce Pharmaceuticals Ltd Announces Further Results for its Synthetic Anti-Infective R327

Recce Pharmaceuticals Ltd Announces Positive Data on RECCE 327 Against All Six ESKAPE Pathogens

Recce Pharmaceuticals Ltd Announces Lead Compound Recce 327 Added to the Pew Charitable Trusts' Annual List of Non-Traditional Products